While pharmaceutical executives raise valid concerns about the lack of detailed implementation plans for the “Most Favored ...

(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Trump administration officials are expected to release more details on their plan to lower prescription drug prices in the ...

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Republican presidential candidate Donald Trump has proposed a “Most Favored Nation” pricing plan to lower the cost of ...

WASHINGTON — Trump administration officials are expected to release more details on their plan to lower prescription drug ...

Liquidity is a major risk retail investors need to be aware of as more investment vehicles offer a chance to get access to ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...